ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Prognostic value of
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06926179 (Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer: A Multicenter Real-World Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAlthough pathological complete response (pCR) is generally associated with favorable survival outcomes, 10-15% of patients who achieve pCR after neoadjuvant chemoimmunotherapy still relapse within 3 years. This study aimed to explore the prognostic value of clinical features and metabolic parameters derived from 18-fluorodeoxyglucose positron emission tomography/computed tomography (
methodsWe retrospectively analyzed 121 non-small cell lung cancer (NSCLC) patients with confirmed pCR of both primary tumors and lymph nodes after receiving neoadjuvant chemoimmunotherapy at Peking University Cancer Hospital. Univariate and multivariate Cox regression were used to identify prognostic factors, including clinical features, baseline (pre-neoadjuvant) and second (post-neoadjuvant) metabolic parameters on PET/CT-maximum standardized uptake value (SUVmax), peak standardized uptake value (SUVpeak), metabolic tumor volume (MTV), and total lesion glycolysis (TLG)-as well as their percentage changes prior to surgery.
resultsDuring a median follow-up period of 26 months, 11 patients experienced recurrence or metastasis. The 1-, 2-, and 3-year disease-free survival (DFS) rates were 98%, 92%, and 88%, respectively. PET-defined N2 (HR = 10.32; 95%CI: 1.90-55.99; p = 0.007), squamous cell carcinoma histology (HR = 0.27; 95%CI: 0.07-0.97; p = 0.05), and baseline MTV (HR = 1.02; 95%CI: 1.01-1.03; p = 0.01) were all correlated with DFS among NSCLC patients attaining pCR. When metabolic parameters were dichotomized into high and low groups, those pCR patients with higher metabolic activity had significantly shorter DFS than those with lower activity did. The corresponding hazard ratios for baseline PET/CT parameters were as follows: SUVpeak, 10.17 (95% CI: 1.3-79.51); MTV, 4.26 (95% CI: 1.13-16.1); and TLG, 8.43 (95% CI: 1.08-65.9).
conclusionAmong NSCLC patients achieving pCR after neoadjuvant chemoimmunotherapy, multivariable Cox regression analyses revealed that elevated baseline MTV and PET/CT-defined N2 status were independently associated with poor DFS, while squamous histology was associated with more favorable DFS. These findings highlight that even among pCR patients, baseline metabolic, histologic, and nodal staging characteristics retain important prognostic value. CLINICAL REGISTRATION NUMBER: This real-world retrospective trial was registered at ClinicalTrials.gov on April 12th, 2025 (NCT06926179).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.